Obesity and dyslipidemia both increase the risk of hyperuricemia. Orlistat, a lipase inhibitor, may lower uric acid levels in patients with obesity, according to new research. Investigators led by ...

Although safe, Orlistat produces some unpleasant side effects. The fat it removes from ingested food ends up in the stool, where it causes cramping and diarrhea. “You can also have oil leaking out of ...

Clin Lipidology. 2009;4(3):331-341. Furthermore, at 6 months significant in-group changes were observed for body weight, BMI and waist circumference in all treatment groups, but these reductions were ...

Helsinki, Finland - The antiobesity drug orlistat (Xenical ®, Roche) improved cardiovascular risk factors and prevented the development of type 2 diabetes in patients with metabolic syndrome, ...

To assess the cost-effectiveness of orlistat plus a calorie-controlled diet compared with a calorie-controlled diet alone for the treatment of overweight and obese patients in Ireland. Economic ...

Orlistat, the first of a new class of drugs for the treatment of obesity, was launched in the UK in December 1998. The prescribing information recommends that treatment with orlistat should be ...

(HealthDay News) — In overweight and obese patients with type 2 diabetes (T2D), treatment with orlistat in addition to lifestyle modifications improves outcomes, according to research published online ...

Orlistat (Nipocut (120 mg)) is a lipase inhibitor, prescribed for obesity in adults. It works by blocking the digestion of fats from the diet. The information provided on this page is intended to ...

Orlistat (Reeshape) is a lipase inhibitor, prescribed for obesity in adults. It works by blocking the digestion of fats from the diet. The information provided on this page is intended to serve as a ...

Switzerland’s Roche says that it has granted GlaxoSmithKline an exclusive license for the non-prescription rights to its anti-obesity drug orlistat for outside the USA. Switzerland’s Roche says that ...